5-alpha reductase inhibitors are medications that block the conversion of testosterone to dihydrotestosterone (DHT), a hormone linked to conditions like benign prostatic hyperplasia and male pattern baldness. By reducing DHT levels, these inhibitors can help manage symptoms and slow the progression of these conditions.

5-alpha Reductase Inhibitors

Medications

Conversion of testosterone

Dihydrotestosterone (DHT) is a potent androgen derived from testosterone that plays a critical role in the development of male characteristics and is implicated in conditions like androgenetic alopecia and benign prostatic hyperplasia. It is synthesized in the body through the action of the enzyme 5-alpha reductase and binds more strongly to androgen receptors than testosterone itself.

Dihydrotestosterone (DHT)

Hormones are chemical messengers produced by glands in the endocrine system that regulate various physiological processes and behaviors by traveling through the bloodstream to target organs and tissues. They play a crucial role in growth, metabolism, reproduction, and mood regulation, maintaining homeostasis in the body.

Hormone

Benign prostatic hyperplasia (BPH) is a non-cancerous enlargement of the prostate gland, commonly affecting older men, leading to urinary symptoms such as difficulty in starting urination and increased frequency. It is caused by hormonal changes and can be managed through lifestyle modifications, medications, or surgical interventions depending on severity.

Benign Prostatic Hyperplasia

Male pattern baldness, also known as androgenetic alopecia, is a genetically determined condition where hair loss occurs in a well-defined pattern, primarily affecting the top and front of the scalp. While its onset can be influenced by hormonal changes and age, effective treatments, including medications and surgical options, can help manage its progression.

Concepts

Relevant Degrees

Your Lessons